Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US8399469 | OTSUKA | Low hygroscopic aripiprazole drug substance and processes for the preparation thereof |
Jun, 2025
(27 days ago) |
Drugs and Companies using ARIPIPRAZOLE ingredient
Market Authorisation Date: 27 April, 2023
Treatment: NA
Dosage: SUSPENSION, EXTENDED RELEASE
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US8399469 | OTSUKA PHARM CO LTD | Low hygroscopic aripiprazole drug substance and processes for the preparation thereof |
Jun, 2025
(27 days ago) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Dosage Form(NDF) | Feb 28, 2016 |
M(M-150) | Dec 05, 2017 |
New Indication(I-746) | Jul 27, 2020 |
Drugs and Companies using ARIPIPRAZOLE ingredient
Market Authorisation Date: 28 February, 2013
Treatment: NA
Dosage: FOR SUSPENSION, EXTENDED RELEASE
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7500444 (Pediatric) | GLAXO GRP LTD | Actuation indicator for a dispensing device |
Jul, 2025
(22 days ago) |
Drugs and Companies using FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE ingredient
Market Authorisation Date: 08 June, 2006
Treatment: NA
Dosage: AEROSOL, METERED
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US9447415 | SAREPTA THERAPS INC | Antisense oligonucleotides for inducing exon skipping and methods of use thereof |
Jun, 2025
(28 days ago) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Feb 25, 2026 |
Orphan Drug Exclusivity(ODE-347) | Feb 25, 2028 |
Drugs and Companies using CASIMERSEN ingredient
NCE-1 date: 25 February, 2025
Market Authorisation Date: 25 February, 2021
Treatment: NA
Dosage: SOLUTION
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9149579 | KALEO INC | Devices, systems and methods for medicament delivery |
Jul, 2025
(7 days ago) |
Drugs and Companies using EPINEPHRINE ingredient
Market Authorisation Date: 17 November, 2017
Treatment: Method of treating allergic reaction via injection
Dosage: SOLUTION
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7390791 (Pediatric) | GILEAD SCIENCES INC | Prodrugs of phosphonate nucleotide analogues |
Jul, 2025
(19 days ago) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Patient Population(NPP) | Jun 18, 2022 |
New Chemical Entity Exclusivity(NCE) | Feb 07, 2023 |
M(M-82) | Feb 24, 2024 |
Orphan Drug Exclusivity(ODE-256) | Jun 18, 2026 |
New Indication(I-942) | Feb 23, 2027 |
M(M-305) | Apr 24, 2027 |
Orphan Drug Exclusivity(ODE-378) | Oct 07, 2028 |
Orphan Drug Exclusivity(ODE-468) | Feb 23, 2031 |
NCE-1 date: 07 February, 2022
Market Authorisation Date: 07 October, 2021
Treatment: NA
Dosage: TABLET
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7456254 | ASTRAZENECA AB | Polymer-based sustained release device |
Jun, 2025
(26 days ago) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Product(NP) | Jan 27, 2015 |
M(M-162) | Sep 24, 2018 |
M(M-212) | Oct 20, 2020 |
M(M-224) | Apr 02, 2021 |
M(M-240) | Feb 15, 2022 |
New Patient Population(NPP) | Jul 22, 2024 |
Pediatric Exclusivity(PED) | Jan 22, 2025 |
Drugs and Companies using EXENATIDE SYNTHETIC ingredient
Market Authorisation Date: 27 January, 2012
Treatment: As an adjunct to diet and exercise to improve glycemic control in patients 10 to 17 years of age with type 2 diabetes mellitus in combination with metformin and/or sulfonylurea
Dosage: FOR SUSPENSION, EXTENDED RELEASE
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7456254 | ASTRAZENECA AB | Polymer-based sustained release device |
Jun, 2025
(26 days ago) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Product(NP) | Oct 20, 2020 |
M(M-240) | Feb 15, 2022 |
New Patient Population(NPP) | Jul 22, 2024 |
Pediatric Exclusivity(PED) | Jan 22, 2025 |
Drugs and Companies using EXENATIDE SYNTHETIC ingredient
Market Authorisation Date: 20 October, 2017
Treatment: As an adjunct to diet and exercise to improve glycemic control in patients 10 to 17 years of age with type 2 diabetes mellitus in combination with metformin and/or sulfonylurea
Dosage: SUSPENSION, EXTENDED RELEASE
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7456254 | ASTRAZENECA AB | Polymer-based sustained release device |
Jun, 2025
(26 days ago) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
M(M-224) | Apr 02, 2021 |
M(M-240) | Feb 15, 2022 |
New Patient Population(NPP) | Jul 22, 2024 |
Pediatric Exclusivity(PED) | Jan 22, 2025 |
Drugs and Companies using EXENATIDE SYNTHETIC ingredient
Market Authorisation Date: 27 January, 2012
Treatment: As an adjunct to diet and exercise to improve glycemic control in patients 10 to 17 years of age with type 2 diabetes mellitus in combination with insulin alone or insulin plus one other oral antidiab...
Dosage: FOR SUSPENSION, EXTENDED RELEASE
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7390791 (Pediatric) | GILEAD SCIENCES INC | Prodrugs of phosphonate nucleotide analogues |
Jul, 2025
(19 days ago) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Patient Population(NPP) | Sep 28, 2020 |
New Chemical Entity Exclusivity(NCE) | Nov 05, 2020 |
New Indication(I-812) | Oct 03, 2022 |
Orphan Drug Exclusivity(ODE-284) | Sep 28, 2024 |
Orphan Drug Exclusivity(ODE-285) | Sep 28, 2024 |
Orphan Drug Exclusivity(ODE-457) | Jan 07, 2029 |
Drugs and Companies using EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE ingredient
NCE-1 date: 06 November, 2019
Market Authorisation Date: 07 January, 2022
Treatment: NA
Dosage: TABLET
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9186344 | ULTRAGENYX PHARM INC | Glycogen or polysaccharide storage disease treatment method |
Jul, 2025
(25 days ago) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Jun 30, 2025 |
Orphan Drug Exclusivity(ODE-311) | Jun 30, 2027 |
Drugs and Companies using TRIHEPTANOIN ingredient
NCE-1 date: 30 June, 2024
Market Authorisation Date: 30 June, 2020
Treatment: NA
Dosage: LIQUID
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8685444 | ALPHARMA PHARMS | Sequestering subunit and related compositions and methods |
Jul, 2025
(23 days ago) | |
US8685443 | ALPHARMA PHARMS | Sequestering subunit and related compositions and methods |
Jul, 2025
(23 days ago) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Combination(NC) | Aug 13, 2012 |
Drugs and Companies using MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE ingredient
Market Authorisation Date: 13 August, 2009
Treatment: Management of pain severe enough to require daily, around-the-clock, long term opioid treatment by orally administering a plurality of composite subunits as claimed
Dosage: CAPSULE, EXTENDED RELEASE
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8101659 (Pediatric) | NOVARTIS PHARMS CORP | Methods of treatment and pharmaceutical composition |
Jul, 2025
(11 days ago) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Jul 07, 2020 |
New Patient Population(NPP) | Oct 01, 2022 |
Pediatric Exclusivity(PED) | Apr 01, 2023 |
M(M-82) | Feb 16, 2024 |
Drugs and Companies using SACUBITRIL; VALSARTAN ingredient
NCE-1 date: 01 April, 2022
Market Authorisation Date: 07 July, 2015
Treatment: NA
Dosage: TABLET
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US9018368 | SAREPTA THERAPS INC | Antisense oligonucleotides for inducing exon skipping and methods of use thereof |
Jun, 2025
(28 days ago) | |
US10781451 | SAREPTA THERAPS INC | Antisense oligonucleotides for inducing exon skipping and methods of use thereof |
Jun, 2025
(28 days ago) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
USRE47751 | SAREPTA THERAPS INC | Antisense oligonucleotides for inducing exon skipping and methods of use thereof |
Jun, 2025
(28 days ago) | |
US8486907 | SAREPTA THERAPS INC | Antisense oligonucleotides for inducing exon skipping and methods of use thereof |
Jun, 2025
(28 days ago) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Sep 19, 2021 |
Orphan Drug Exclusivity(ODE) | Sep 19, 2023 |
Orphan Drug Exclusivity(ODE-122) | Sep 19, 2023 |
Drugs and Companies using ETEPLIRSEN ingredient
NCE-1 date: 19 September, 2020
Market Authorisation Date: 19 September, 2016
Treatment: Treatment of duchenne muscular dystrophy (dmd) in patients having a mutation of the dmd gene that is amenable to exon 51 skipping by inducing skipping of exon 51; (i)treatment of duchenne muscular dys...
Dosage: SOLUTION
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7456254 | ASTRAZENECA AB | Polymer-based sustained release device |
Jun, 2025
(26 days ago) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
M(M-157) | Mar 11, 2018 |
New Chemical Entity Exclusivity(NCE) | Jan 08, 2019 |
M(M-212) | Oct 20, 2020 |
M(M-238) | Feb 22, 2022 |
New Indication(I-841) | Oct 18, 2022 |
New Indication(I-834) | May 05, 2023 |
New Indication(I-857) | Apr 30, 2024 |
M(M-298) | May 08, 2026 |
New Patient Population(NPP) | Jun 12, 2027 |
Pediatric Exclusivity(PED) | Dec 12, 2027 |
Drugs and Companies using DAPAGLIFLOZIN ingredient
NCE-1 date: 12 December, 2026
Market Authorisation Date: 08 January, 2014
Treatment: Treatment of type 2 diabetes mellitus in combination with exenatide
Dosage: TABLET
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7500444 (Pediatric) | GLAXO GRP LTD | Actuation indicator for a dispensing device |
Jul, 2025
(22 days ago) |
Drugs and Companies using FLUTICASONE PROPIONATE ingredient
Market Authorisation Date: 14 May, 2004
Treatment: NA
Dosage: AEROSOL, METERED
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7390791 (Pediatric) | GILEAD SCIENCES INC | Prodrugs of phosphonate nucleotide analogues |
Jul, 2025
(19 days ago) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Patient Population(NPP) | Sep 25, 2020 |
New Chemical Entity Exclusivity(NCE) | Nov 05, 2020 |
New Dosing Schedule(D-173) | Dec 10, 2021 |
NCE-1 date: 06 November, 2019
Market Authorisation Date: 05 November, 2015
Treatment: NA
Dosage: TABLET
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9339472 | ASTRAZENECA AB | Coated tablet formulation and method |
Jul, 2025
(13 days ago) | |
US8628799 | ASTRAZENECA AB | Coated tablet formulation and method |
Jul, 2025
(13 days ago) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Jul 31, 2014 |
M(M-134) | May 24, 2016 |
M(M-175) | Apr 05, 2019 |
M(M-198) | Feb 27, 2020 |
Drugs and Companies using METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE ingredient
NCE-1 date: 31 July, 2013
Market Authorisation Date: 05 November, 2010
Treatment: NA
Dosage: TABLET, EXTENDED RELEASE
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US7994364 | COLLEGIUM PHARM INC | Crystalline forms of (−)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochloride |
Jun, 2025
(29 days ago) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Nov 20, 2013 |
New Patient Population(NPP) | Jul 03, 2026 |
Pediatric Exclusivity(PED) | Jan 03, 2027 |
Drugs and Companies using TAPENTADOL HYDROCHLORIDE ingredient
NCE-1 date: 03 January, 2026
Market Authorisation Date: 20 November, 2008
Treatment: Management of moderate to severe acute pain
Dosage: TABLET; SOLUTION
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US7994364 | COLLEGIUM PHARM INC | Crystalline forms of (−)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochloride |
Jun, 2025
(29 days ago) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Nov 20, 2013 |
New Dosage Form(NDF) | Aug 25, 2014 |
New Indication(I-656) | Aug 28, 2015 |
Drugs and Companies using TAPENTADOL HYDROCHLORIDE ingredient
NCE-1 date: 20 November, 2012
Market Authorisation Date: 25 August, 2011
Treatment: Relief of moderate to severe chronic pain
Dosage: TABLET, EXTENDED RELEASE
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7390791 (Pediatric) | GILEAD SCIENCES INC | Prodrugs of phosphonate nucleotide analogues |
Jul, 2025
(19 days ago) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
M(M-206) | Aug 21, 2020 |
M(M-207) | Aug 21, 2020 |
New Chemical Entity Exclusivity(NCE) | Nov 05, 2020 |
NCE-1 date: 06 November, 2019
Market Authorisation Date: 01 March, 2016
Treatment: NA
Dosage: TABLET
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9629821 | FRESENIUS KABI USA | Treatment and prevention of liver disease associated with parenteral nutrition (PN) |
Jul, 2025
(15 days ago) | |
US9566260 | FRESENIUS KABI USA | Treatment and prevention of liver disease associated with parenteral nutrition (PN) |
Jul, 2025
(15 days ago) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Jul 27, 2023 |
Orphan Drug Exclusivity(ODE-202) | Jul 27, 2025 |
Drugs and Companies using FISH OIL TRIGLYCERIDES ingredient
NCE-1 date: 27 July, 2022
Market Authorisation Date: 27 July, 2018
Treatment: Use for patients with parenteral nutrition associated cholestasis or parenteral nutrition associated liver disease; Treatment of liver disease through nutrition for patients under the age of 12
Dosage: EMULSION
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US6245819 | DUCHESNAY | Method for the treatment of vaginal dryness and sexual dysfunction in women during or after the menopause |
Jul, 2025
(5 days ago) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Feb 26, 2018 |
New Indication(I-793) | Jan 25, 2022 |
Drugs and Companies using OSPEMIFENE ingredient
NCE-1 date: 26 February, 2017
Market Authorisation Date: 26 February, 2013
Treatment: Treatment of dyspareunia associated with menopause
Dosage: TABLET
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US7547719 | NOVARTIS | 3′-[(2z)-[1-(3,4-Dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4h-pyrazol-4-ylidene]hy-drazino]-2′-hydroxy-[1,1′-piphenyl]-acid bis-(monoethanolamine) |
Jul, 2025
(13 days ago) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Nov 20, 2013 |
New Indication(I-664) | Nov 16, 2015 |
Orphan Drug Exclusivity(ODE) | Nov 20, 2015 |
New Dosing Schedule(D-149) | Jun 11, 2018 |
New Indication(I-711) | Jun 11, 2018 |
Orphan Drug Exclusivity(ODE-75) | Aug 26, 2021 |
Pediatric Exclusivity(PED) | Feb 26, 2022 |
Orphan Drug Exclusivity(ODE-210) | Nov 16, 2025 |
Drugs and Companies using ELTROMBOPAG OLAMINE ingredient
NCE-1 date: 26 February, 2021
Market Authorisation Date: 20 October, 2011
Treatment: Combination with immunosuppressive therapy for first-line treatment of adult and pediatric patients 2 years and older with severe aplastic anemia
Dosage: TABLET
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US7547719 | NOVARTIS | 3′-[(2z)-[1-(3,4-Dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4h-pyrazol-4-ylidene]hy-drazino]-2′-hydroxy-[1,1′-piphenyl]-acid bis-(monoethanolamine) |
Jul, 2025
(13 days ago) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Dosing Schedule(D-149) | Jun 11, 2018 |
New Indication(I-711) | Jun 11, 2018 |
Orphan Drug Exclusivity(ODE) | Aug 26, 2021 |
Orphan Drug Exclusivity(ODE-74) | Aug 26, 2021 |
Pediatric Exclusivity(PED) | Feb 26, 2022 |
ODE*(ODE*) | Nov 16, 2025 |
Drugs and Companies using ELTROMBOPAG OLAMINE ingredient
Market Authorisation Date: 27 September, 2018
Treatment: Treatment of thrombocytopenia in patients with chronic hepatitis c to allow the initiation and maintenance of interferon-based therapy
Dosage: FOR SUSPENSION
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8628799 | ASTRAZENECA AB | Coated tablet formulation and method |
Jul, 2025
(13 days ago) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Jan 08, 2019 |
M(M-175) | Apr 05, 2019 |
New Combination(NC) | Feb 27, 2020 |
New Indication(I-804) | May 02, 2022 |
New Strength(NS) | May 02, 2022 |
Drugs and Companies using DAPAGLIFLOZIN; SAXAGLIPTIN HYDROCHLORIDE ingredient
NCE-1 date: 08 January, 2018
Market Authorisation Date: 02 May, 2019
Treatment: NA
Dosage: TABLET
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8628799 | ASTRAZENECA AB | Coated tablet formulation and method |
Jul, 2025
(13 days ago) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Product(NP) | May 02, 2022 |
Market Authorisation Date: 02 May, 2019
Treatment: NA
Dosage: TABLET, EXTENDED RELEASE
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7758890 | EAGLE PHARMS | Treatment using dantrolene |
Jun, 2025
(26 days ago) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
Orphan Drug Exclusivity(ODE) | Jul 22, 2021 |
Orphan Drug Exclusivity(ODE-69) | Jul 22, 2021 |
Drugs and Companies using DANTROLENE SODIUM ingredient
Market Authorisation Date: 22 July, 2014
Treatment: NA
Dosage: FOR SUSPENSION
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8685443 | PFIZER | Sequestering subunit and related compositions and methods |
Jul, 2025
(23 days ago) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Combination(NC) | Aug 19, 2019 |
Drugs and Companies using NALTREXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE ingredient
Market Authorisation Date: 19 August, 2016
Treatment: Management of pain severe enough to require daily, around-the-clock, long term opioid treatment by orally administering a plurality of composite subunits as claimed
Dosage: CAPSULE, EXTENDED RELEASE
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8927497 | NEURELIS INC | Absorption enhancers for intranasal administration |
Jul, 2025
(5 days ago) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Product(NP) | Jan 10, 2023 |
Orphan Drug Exclusivity(ODE-279) | Jan 10, 2027 |
New Patient Population(NPP) | Apr 15, 2028 |
Drugs and Companies using DIAZEPAM ingredient
Market Authorisation Date: 10 January, 2020
Treatment: Nasal administration of diazepam for the acute treatment of intermittent, stereotypic episodes of frequent seizure activity that are distinct from a patient's usual seizure pattern in patients with ep...
Dosage: SPRAY
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7390791 (Pediatric) | GILEAD SCIENCES INC | Prodrugs of phosphonate nucleotide analogues |
Jul, 2025
(19 days ago) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Product(NP) | Nov 11, 2019 |
New Chemical Entity Exclusivity(NCE) | Nov 05, 2020 |
M(M-255) | Feb 04, 2023 |
M(M-266) | Aug 22, 2023 |
New Patient Population(NPP) | Oct 17, 2025 |
Drugs and Companies using TENOFOVIR ALAFENAMIDE FUMARATE ingredient
NCE-1 date: 06 November, 2019
Market Authorisation Date: 10 November, 2016
Treatment: NA
Dosage: TABLET
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7500444 (Pediatric) | GLAXOSMITHKLINE | Actuation indicator for a dispensing device |
Jul, 2025
(22 days ago) |
Drugs and Companies using ALBUTEROL SULFATE ingredient
Market Authorisation Date: 19 April, 2001
Treatment: NA
Dosage: AEROSOL, METERED
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9770406 | ANI PHARMS | Medicament for the treatment of viral skin and tumour diseases |
Jul, 2025
(14 days ago) |
Drugs and Companies using SINECATECHINS ingredient
Market Authorisation Date: 31 October, 2006
Treatment: Treatment of genital warts
Dosage: OINTMENT
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US6794489 | COSETTE | Compositions and methods for treatment of sexual dysfunction |
Jun, 2025
(28 days ago) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Jun 21, 2024 |
Drugs and Companies using BREMELANOTIDE ACETATE ingredient
NCE-1 date: 22 June, 2023
Market Authorisation Date: 21 June, 2019
Treatment: NA
Dosage: SOLUTION
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US10227590 | SAREPTA THERAPS INC | Antisense oligonucleotides for inducing exon skipping and methods of use thereof |
Jun, 2025
(28 days ago) | |
US9994851 | SAREPTA THERAPS INC | Antisense oligonucleotides for inducing exon skipping and methods of use thereof |
Jun, 2025
(28 days ago) | |
US10421966 | SAREPTA THERAPS INC | Antisense oligonucleotides for inducing exon skipping and methods of use thereof |
Jun, 2025
(28 days ago) | |
US9024007 | SAREPTA THERAPS INC | Antisense oligonucleotides for inducing exon skipping and methods of use thereof |
Jun, 2025
(28 days ago) | |
US10968450 | SAREPTA THERAPS INC | Antisense oligonucleotides for inducing exon skipping and methods of use thereof |
Jun, 2025
(28 days ago) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10995337 | SAREPTA THERAPS INC | Antisense oligonucleotides for inducing exon skipping and methods of use thereof |
Jun, 2025
(28 days ago) | |
US10266827 | SAREPTA THERAPS INC | Antisense oligonucleotides for inducing exon skipping and methods of use thereof |
Jun, 2025
(28 days ago) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Dec 12, 2024 |
Orphan Drug Exclusivity(ODE-280) | Dec 12, 2026 |
Drugs and Companies using GOLODIRSEN ingredient
NCE-1 date: 13 December, 2023
Market Authorisation Date: 12 December, 2019
Treatment: Treatment of duchenne muscular dystrophy (dmd) in patients having a confirmed mutation of the dmd gene that is amenable to exon 53 skipping
Dosage: SOLUTION
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8865690 | SUN PHARM | 17alfa, 21-dihydroxypregnene esters as antiandrogenic agents |
Jul, 2025
(2 days ago) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Aug 26, 2025 |
Drugs and Companies using CLASCOTERONE ingredient
NCE-1 date: 26 August, 2024
Market Authorisation Date: 26 August, 2020
Treatment: Method of treating acne vulgaris with topically applied cortexolone 17a-propionate
Dosage: CREAM
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
USRE44599 | GILEAD SCIENCES INC | Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta |
Jul, 2025
(5 days ago) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Jul 23, 2019 |
Orphan Drug Exclusivity(ODE) | Jul 23, 2021 |
Orphan Drug Exclusivity(ODE-70) | Jul 23, 2021 |
Orphan Drug Exclusivity(ODE-71) | Jul 23, 2021 |
Drugs and Companies using IDELALISIB ingredient
NCE-1 date: 23 July, 2018
Market Authorisation Date: 23 July, 2014
Treatment: For the treatment of patients with cll, fl, or sll
Dosage: TABLET